In this episode, we dive into the "New Space" frontier with James Kingsnorth, a scientist at Tumbleweed. We explore how removing the "noise" of gravity allows pharmaceutical and biotech companies to discover biological structures that are impossible to replicate on Earth. From the success of Merck's Keytruda in microgravity to the creation of complex 3D organoids, this conversation highlights how orbital research is no longer a distant dream but a practical, accessible tool for modern science.

James explains how Tumbleweed is lowering the barriers to entry by replacing years of bureaucratic paperwork and ISS backlogs with a streamlined "plug-and-play" satellite service. We discuss the radical cost reductions in space access and why the next decade of drug manufacturing might just happen 400 kilometers above our heads.

Subjects Covered:

The Science of Zero-G: How removing convection and sedimentation leads to more uniform protein crystals and complex 3D structures.
Case Study (Keytruda): How Merck used microgravity to refine drug delivery, reducing treatment time from 60 minutes to 60 seconds.
Accelerated Aging: Using the harsh environment of space as a "time machine" to study immunology and disease progression in days rather than years.
Democratizing Access: How SpaceX and reusable rockets have plummeted the cost of research per kilogram.
The "Pod" Concept: Tumbleweed’s isolated, pre-certified hardware that removes the need for complex safety certifications.
The Future of Space Manufacturing: The transition from human-led experiments on the ISS to autonomous, miniaturized orbital labs.
The Return Journey: The logistics of de-orbiting experiments and recovering data for terrestrial application.

Credits :

Production : MedShake Studio

Animation : Anca Petre

Hosted on Ausha. See ausha.co/privacy-policy for more information.